Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9H4W6
UPID:
COE3_HUMAN
Alternative names:
Early B-cell factor 3; Olf-1/EBF-like 2
Alternative UPACC:
Q9H4W6; A0AUY1; Q5T6H9; Q9H4W5
Background:
Transcription factor COE3, also known as Early B-cell factor 3 and Olf-1/EBF-like 2, plays a pivotal role in gene expression regulation. It activates transcription by recognizing variations of the palindromic sequence 5'-ATTCCCNNGGGAATT-3'. This protein's involvement in neurodevelopmental processes is underscored by its association with Hypotonia, ataxia, and delayed development syndrome, a condition marked by developmental delays and cerebellar ataxia.
Therapeutic significance:
Given its crucial role in neurodevelopment, targeting Transcription factor COE3 could offer novel therapeutic avenues for treating Hypotonia, ataxia, and delayed development syndrome. Understanding the protein's function and its genetic variants could pave the way for precision medicine approaches in neurodevelopmental disorders.